ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CT) ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Computed Tomography Market Size, Share & Trends Analysis Report By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1474880
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 195 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
CT(ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ) ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ CT ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 78¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£ Áß CAGRÀº 7.87%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ÉÇ÷°ü Áúȯ, ¾Ï°ú °°Àº ¸¸¼ºÁúȯÀÇ ºÎ´ã Áõ°¡¿Í È¿°úÀûÀÎ À̹Ì¡ Åø¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä´Â ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. ±¹Á¦¾Ï¿¬±¸¼Ò¿¡ µû¸£¸é 2020³â Àü ¼¼°è¿¡¼ ¾à 19,292,789¸íÀÇ ½Å±Ô ¾Ï ȯÀÚ°¡ ¹ß»ýÇßÀ¸¸ç, 9,958,133¸íÀÌ »ç¸ÁÇß½À´Ï´Ù. 2025³â±îÁö ¾Ï À¯º´·üÀº 50,550,287¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¶ÇÇÑ ¿¹Ãø ±â°£ Áß ÀÀ±ÞÀÇ·á ºÎ¹®ÀÇ CT ½Ã½ºÅÛ ¼ö¿ä Áõ°¡°¡ ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼±·® °ü¸® ½Ã½ºÅÛ, ¿òÁ÷ÀÓÀ» ÅëÇÑ Á¾¾ç Áø´Ü ±â´É(4D), ÀΰøÁö´É ÅëÇÕ, °í±Þ ¼ÒÀç Â÷º°È µîÀÇ ±â´ÉÀ» °®Ãá ÷´Ü ±â¼úÀÌ ±âÁ¸ÀÇ ±âÁ¸ Àåºñ¸¦ ´ëüÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2021³â 9¿ù GEÇコÄɾî´Â ÀΰøÁö´É(AI)À» ÅëÇÕÇÏ¿© ¾÷¹« È¿À²¼º°ú ȯÀÚ ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â ±â¼úÀ» žÀçÇÑ CT ½Ã½ºÅÛ '·¹º¼·ç¼Ç ¾î¼¾µå(Revolution Ascend)'¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ±â¼úÀ» žÀçÇÑ CT ½Ã½ºÅÛ '·¹º¼·ç¼Ç ¾î¼¾µå(Revolution Ascend)¸¦ ¹ßÇ¥Çß½À´Ï´Ù. Á¤ºÎ»Ó¸¸ ¾Æ´Ï¶ó ¹Î°£´ÜüÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥ Áõ°¡µµ ½ÃÀåÀ» À¯¸®ÇÑ ¼Óµµ·Î °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °æÁ¦¼º °³¼±À¸·Î ÀÎÇÑ ¿Ü·¡ Áø´Ü¼¾ÅÍ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¿ø°ÝÁö¿¡ ´ëÇÑ CT ½ºÄ³³ÊÀÇ º¸±ÞÀº Ãß°¡ÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ ´ëü ¿µ»ó ±â¼úÀº ½Å¼ÓÇÑ º¸°í°¡ ºÒ°¡´ÉÇÏ°í µ¿½Ã¿¡ ºñ¿ë È¿À²¼ºÀÌ ³·±â ¶§¹®¿¡ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Àåºñ¿Í ±â¼úÀº Á¤±âÀûÀ¸·Î ¾÷±×·¹À̵åµÇ±â ¶§¹®¿¡ ¿¹Ãø ±â°£ Áß ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, COVID-19 ÆÒµ¥¹ÍÀÌ ½ÃÀÛµÈ ÀÌÈÄ CT ½ºÄ³³Ê¿¡ ´ëÇÑ ¼ö¿ä´Â Á¡Â÷ Áõ°¡Çϰí ÀÖÀ¸¸ç, Siemens Healthineers¿Í °°Àº ´ë±â¾÷Àº ¸Å³â 200´ë ÀÌ»óÀÇ CT ½ºÄ³³Ê¸¦ ÆÇ¸ÅÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ CT ½ºÄµ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ¿© Áö¸à½º´Â ´Ü 45ÀÏ ¸¸¿¡ 80-100´ëÀÇ CT ½ºÄ³³Ê¸¦ ÆÇ¸ÅÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¶ÇÇÑ COVID-19 ȯÀÚÀÇ ÈäºÎ CT °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖ¿ä Á¦Á¶¾÷üµéÀº CT ÀåºñÀÇ »ý»ê ´É·ÂÀ» °ÈÇß½À´Ï´Ù.
CT ½ÃÀå º¸°í¼ÀÇ ÁÖ¿ä ³»¿ë
- °í±ÞÇü ½½¶óÀ̽º CT ºÎ¹®ÀÌ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °í±Þ À̹ÌÁö ǰÁúÀ» Çâ»ó½ÃŰ´Â ÷´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í °íǰÁú ÀÇ·á ¼ºñ½º Á¦°øÀ¸·ÎÀÇ ÀüȯÀÌ ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 2023³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ´ë±Ô¸ð ȯÀÚ Ç®°ú Ä¡·á Áß Áø´Ü Åø·Î¼ CT ½ºÄ³³Ê¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì°¡ 2023³â ½ÃÀåÀ» µ¶Á¡ÇÑ ÀÌÀ¯´Â ÷´Ü ±â¼ú äÅ÷üÀÌ ³ô°í, ´Ù¼ö ½ÃÀå ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù.
- ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÷´Ü À̹Ì¡ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¿µ»ó Áø´Ü¼¾ÅÍ Áõ°¡´Â ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.
- ¾÷°è ÁÖ¿ä ±â¾÷Àº ÀΰøÁö´É Áö¿ø, µà¾ó ¼Ò½º °ËÃâ±â ±â¼ú ±â¹Ý CT ½ºÄ³³Ê µî ÷´Ü ±â¼ú ¹× ±â´É Ãâ½Ã¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå CT ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ¸ð½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ ºÐ¼®
- CT ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå CT ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®
- ±â¼úÀÇ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ CT ½ÃÀå, ±â¼úº° Àü¸Á
- 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®
- ÇÏÀÌ¿£µå ½½¶óÀ̽º CT
- ¹Ìµå¿£µå ½½¶óÀ̽º CT
- ·Î¿£µå ½½¶óÀ̽º CT
- Äܺö CT
Á¦5Àå CT ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¿ëµµÀÇ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ CT ½ÃÀå, ¿ëµµº° Àü¸Á
- 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®
- Á¾¾ç
- ½ÉÀ庴
- Ç÷°ü
- ½Å°æ
- ±Ù°ñ°Ý
- ±âŸ
Á¦6Àå CT ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµÀÇ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ CT ½ÃÀå, ÃÖÁ¾ ¿ëµµº° Àü¸Á
- 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®
- º´¿ø
- ¿µ»ó Áø´Ü ¼¾ÅÍ
- ±âŸ
Á¦7Àå CT ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªÀÇ ½ÃÀå ´ë½Ãº¸µå
- ¼¼°èÀÇ Áö¿ªÀÇ ½ÃÀå ½º³À¼ô
- 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷/°æÀï ºÐ·ù
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
- ±â¾÷ Æ÷Áö¼Ç ºÐ¼®, 2023³â
- ±â¾÷ ºÐ·ù(½Å±Ô ±â¾÷, À̳뺣ÀÌÅÍ, ¸®´õ)
- ±â¾÷ °³¿ä
- GE HealthCare
- Koninklijke Philips NV
- Siemens Healthineers AG
- Canon Medical Systems
- NeuroLogica Corp.
- Shanghai United Imaging Healthcare Co., Ltd.
- Fujifilm Holdings Corporation
- Shenzhen Anke High-tech Co., Ltd
- Koning Health
- Carestream Dental LLC.
KSA
¿µ¹® ¸ñÂ÷
Computed Tomography Market Growth & Trends:
The global computed tomography market size is expected to reach USD 7.81 billion by 2030, registering a CAGR of 7.87% during the forecast period, according to a new report by Grand View Research, Inc. The increasing burden of chronic disorders, such as cardiovascular diseases and cancer, and the high demand for effective imaging tools are the factors driving growth. According to the International Agency for Cancer on Research, in 2020 globally there were about 19,292,789 new cancer cases with 9,958,133 deaths. The same source stated that the prevalence of cancer is predicted to increase to 50,550,287 by 2025. In addition, increasing demand for computed tomography (CT) systems in emergency care departments are expected to be a major driver during the forecast period.
Advanced technology with features such as dose management systems, the ability to diagnose tumors through motion (4D), artificial intelligence integration, and high-end material differentiation is expected to replace the existing conventional devices. In September 2021, GE Healthcare introduced the Revolution Ascend CT system, the technology that combines artificial intelligence (AI) to improve operational efficiency and patient comfort. The increasing number of favorable reimbursement policies by the government as well as private entities are also expected to drive the market at a lucrative pace. Growing demand for ambulatory diagnostic centers due to improving affordability and increasing reach of CT scanners to remote regions is expected to aid further growth.
Moreover, the inability of alternative imaging technologies to provide quick reports and at the same time be cost-effective boosts growth. These devices and this technology are also routinely upgraded, which is expected to further increase demand over the forecast period. Since the start of the COVID-19 pandemic, demand for CT scanners gradually increased. Large companies like Siemens Healthineers are known to sell over 200 CT scanners each year. The COVID-19 pandemic has resulted in a significant surge in CT scan equipment demand, with Siemens reporting sales of 80 to 100 units in only 45 days. Furthermore, due to increased demand for chest CT examinations in COVID-19 patients, major manufacturers increased the production capacity of the CT system.
Computed Tomography Market Report Highlights:
- The high-end slice CT segment held the largest market share in 2023, the increasing demand for advanced technology with enhanced imaging quality and the shifting focus on providing quality healthcare services has contributed to this growth
- Based on end-use, the hospital segment captured the largest revenue share in 2023, the large patient pool and high demand for CT scanners as a diagnostic tool during treatment are expected to contribute to the growth of this segment
- North America dominated the market in 2023, owing to the high adoption of advanced technology and the presence of a large number of market players are some of the factors that can be attributed to this share
- Asia Pacific is expected to grow at the fastest rate over the forecast period, growing demand for advanced imaging techniques and the rising number of diagnostic imaging centers are some of the factors driving regional growth
- Major players in the industry are focusing on the launch of advanced technology and features such as artificial intelligence-enabled, dual source-detector technology-based CT scanners.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Application
- 1.2.3. End-use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Computed Tomography Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growing prevalence of cancer and cardiac disease
- 3.2.1.2. Rising geriatric population
- 3.2.1.3. Technological advancements in the computed tomography devices
- 3.2.2. Market restraint analysis
- 3.2.2.1. Risk of radiation exposure
- 3.2.2.2. Lack of skilled radiologists and high cost of medical imaging devices
- 3.2.3. Market challenge analysis
- 3.2.3.1. Increasing use of refurbished products
- 3.2.3.2. Lack of regulations in the developing countries
- 3.3. Computed Tomography Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
Chapter 4. Computed Tomography Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Computed Tomography Market by Technology Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. High-end Slice CT
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Mid-end Slice CT
- 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Low-end Slice CT
- 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Cone Beam CT
- 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Computed Tomography Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Computed Tomography Market by Application Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Oncology
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Cardiology
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Vascular
- 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Neurology
- 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.9. Musculoskeletal
- 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.10. Others
- 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Computed Tomography Market: End-use Estimates & Trend Analysis
- 6.1. End Use Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Computed Tomography Market by End Use Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5. Hospitals
- 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Diagnostic Imaging Centers
- 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Others
- 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Computed Tomography Market: Regional Estimates & Trend Analysis by Country, Technology, Application, and End-use
- 7.1. Regional Market Dashboard
- 7.2. Global Regional Market Snapshot
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework
- 7.4.1.3. Reimbursement structure
- 7.4.1.4. Competitive scenario
- 7.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Reimbursement structure
- 7.4.2.4. Competitive scenario
- 7.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework
- 7.5.1.3. Reimbursement structure
- 7.5.1.4. Competitive scenario
- 7.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Reimbursement structure
- 7.5.2.4. Competitive scenario
- 7.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Reimbursement structure
- 7.5.3.4. Competitive scenario
- 7.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Reimbursement structure
- 7.5.4.4. Competitive scenario
- 7.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Reimbursement structure
- 7.5.5.4. Competitive scenario
- 7.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Reimbursement structure
- 7.5.6.4. Competitive scenario
- 7.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework
- 7.5.7.3. Reimbursement structure
- 7.5.7.4. Competitive scenario
- 7.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework
- 7.5.8.3. Reimbursement structure
- 7.5.8.4. Competitive scenario
- 7.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework
- 7.6.1.3. Reimbursement structure
- 7.6.1.4. Competitive scenario
- 7.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Reimbursement structure
- 7.6.2.4. Competitive scenario
- 7.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework
- 7.6.3.3. Reimbursement structure
- 7.6.3.4. Competitive scenario
- 7.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework
- 7.6.4.3. Reimbursement structure
- 7.6.4.4. Competitive scenario
- 7.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework
- 7.6.5.3. Reimbursement structure
- 7.6.5.4. Competitive scenario
- 7.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework
- 7.6.6.3. Reimbursement structure
- 7.6.6.4. Competitive scenario
- 7.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework
- 7.7.1.3. Reimbursement structure
- 7.7.1.4. Competitive scenario
- 7.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Mexico
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Reimbursement structure
- 7.7.2.4. Competitive scenario
- 7.7.2.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework
- 7.7.3.3. Reimbursement structure
- 7.7.3.4. Competitive scenario
- 7.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework
- 7.8.1.3. Reimbursement structure
- 7.8.1.4. Competitive scenario
- 7.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework
- 7.8.2.3. Reimbursement structure
- 7.8.2.4. Competitive scenario
- 7.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework
- 7.8.3.3. Reimbursement structure
- 7.8.3.4. Competitive scenario
- 7.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework
- 7.8.4.3. Reimbursement structure
- 7.8.4.4. Competitive scenario
- 7.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Key Company Market Share Analysis, 2023
- 8.4. Company Position Analysis, 2023
- 8.5. Company Categorization (Emerging Players, Innovators, and Leaders)
- 8.6. Company Profiles
- 8.6.1. GE HealthCare
- 8.6.1.1. Company overview
- 8.6.1.2. Financial performance
- 8.6.1.3. Product benchmarking
- 8.6.1.4. Strategic initiatives
- 8.6.2. Koninklijke Philips N.V.
- 8.6.2.1. Company overview
- 8.6.2.2. Financial performance
- 8.6.2.3. Product benchmarking
- 8.6.2.4. Strategic initiatives
- 8.6.3. Siemens Healthineers AG
- 8.6.3.1. Company overview
- 8.6.3.2. Financial performance
- 8.6.3.3. Product benchmarking
- 8.6.3.4. Strategic initiatives
- 8.6.4. Canon Medical Systems
- 8.6.4.1. Company overview
- 8.6.4.2. Financial performance
- 8.6.4.3. Product benchmarking
- 8.6.4.4. Strategic initiatives
- 8.6.5. NeuroLogica Corp.
- 8.6.5.1. Company overview
- 8.6.5.2. Financial performance
- 8.6.5.3. Product benchmarking
- 8.6.5.4. Strategic initiatives
- 8.6.6. Shanghai United Imaging Healthcare Co., Ltd.
- 8.6.6.1. Company overview
- 8.6.6.2. Financial performance
- 8.6.6.3. Product benchmarking
- 8.6.6.4. Strategic initiatives
- 8.6.7. Fujifilm Holdings Corporation
- 8.6.7.1. Company overview
- 8.6.7.2. Financial performance
- 8.6.7.3. Product benchmarking
- 8.6.7.4. Strategic initiatives
- 8.6.8. Shenzhen Anke High-tech Co., Ltd
- 8.6.8.1. Company overview
- 8.6.8.2. Financial performance
- 8.6.8.3. Product benchmarking
- 8.6.8.4. Strategic initiatives
- 8.6.9. Koning Health
- 8.6.9.1. Company overview
- 8.6.9.2. Financial performance
- 8.6.9.3. Product benchmarking
- 8.6.9.4. Strategic initiatives
- 8.6.10. Carestream Dental LLC.
- 8.6.10.1. Company overview
- 8.6.10.2. Financial performance
- 8.6.10.3. Product benchmarking
- 8.6.10.4. Strategic initiatives
°ü·ÃÀÚ·á